In Vivo Monitoring Response to Chemotherapy of Human Diffuse Large B-Cell Lymphoma Xenografts in SCID Mice by 1H and 31P MRS

Academic Radiology

Volumn 14, Issue 12, 2007, Pages 1531-1539

  Huang, Ming Q ^a   Nelson, David S ^a   Pickup, Stephen ^a   Qiao, Hui ^a   Delikatny, E James ^a   Poptani, Harish ^a   Glickson, Jerry D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Grant sponsor: NIH (grant R01 CA101700 01A1)   (United States)

Author keywords

chemotherapy; choline; lactate; MRS; Non Hodgkin's lymphoma; therapeutic response

Indexed keywords

BETA NUCLEOSIDE TRIPHOSPHATE; BRYOSTATIN 1; CHOLINE; CYCLOPHOSPHAMIDE; HYDROXY DOXORUBICIN; LACTIC ACID; PHOSPHATASE; PHOSPHATE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCID MOUSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CHOLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEASIBILITY STUDIES; GLYCEROPHOSPHATES; HUMANS; HYDROGEN; LACTATES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NUCLEOTIDES; PHOSPHORUS; PREDNISONE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 36148963313     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2007.07.012     Document Type: Article

References (52)

1. Ansell S.M., and Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1087-1097
2. Rogers B.B. Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs 22 (2006) 67-72
3. Zinzani P.L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 32 (2005) S4-S10
4. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
5. American Cancer Society. Cancer facts & figures 2002 (2002), American Cancer Society, Atlanta
6. American Cancer Society. Cancer facts & figures 2006 (2006), American Cancer Society, Atlanta
7. Fisher R. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 40 (1997) S42-S46
8. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
9. Glickson J.D. Clinical NMR-spectroscopy of tumors-current status and future-directions. Invest Radiol 24 (1989) 1011-1016
10. Ng T.C., Evanochko W.T., Hiramoto R.N., et al. P-31 NMR-spectroscopy of in vivo tumors. J Magn Reson 49 (1982) 271-286
11. Li S.J., Wehrle J.P., Rajan S.S., et al. Response of radiation-induced fibrosarcoma-1 in mice to cyclophosphamide monitored by in vivo P-31 nuclear magnetic-resonance spectroscopy. Cancer Res 48 (1988) 4736-4742
12. Wehrle J.P., Li S.J., Rajan S.S., Steen R.G., et al. P-31 and H-1-NMR spectroscopy of tumors in vivo-untreated growth and response to chemotherapy. Ann NY Acad Sci 508 (1987) 200-215
13. Braunschweiger P.G., Kumar N., Constantinidis I., et al. Potentiation of interleukin 1-alpha mediated antitumor effects by ketoconazole. Cancer Res 50 (1990) 4709-4717
14. Shungu D.C., Bhujwalla Z.M., Wehrle J.P., et al. H-1-NMR spectroscopy of subcutaneous tumors in mice-preliminary studies of effects of growth, chemotherapy and blood-flow reduction. NMRBiomed 5 (1992) 296-302
15. Bhujwalla Z.M., and Glickson J.D. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys 36 (1996) 635-639
16. Griffiths J.R., Tate A.R., Howe F.A., et al., The Multi-Institutional Group on MRS Application to Cancer. Magnetic resonance spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 38 (2002) 2085-2093
17. Zakian K.L., and Koutcher J.A. Magnetic resonance spectroscopy and clinical cancer prognosis. Acad Radiol 11 (2004) 365-367
18. Sibtaina N.A., Howeb F.A., and Saundersc D.E. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 62 (2007) 109-119
19. He Q., Shungu D.C., van Zijl P.C., et al. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC)with application to tumors. J Magn Reson B 106 (1995) 203-211
20. Evanochko W.T., Sakai T.T., Ng T.C., et al. NMR-study of in vivo Rif-1 tumors-analysis of perchloric-acid extracts and identification of H-1-resonances, P-31-resonances and C-13-resonances. Biochim Biophys Acta 805 (1984) 104-116
21. Evelhoch J.L., Sapareto S.A., Nussbaum G.H., et al. Correlations between P-31 NMR-spectroscopy and O-15 perfusion measurements in the Rif-1 murine tumor in vivo. Radiat Res 106 (1986) 122-131
22. Negendank W.G., Padavicshaller K.A., Li C.W., et al. Metabolic characterization of human non-Hodgkins-lymphomas in-vivo with the use of proton-decoupled phosphorus magnetic-resonance spectroscopy. Cancer Res 55 (1995) 3286-3294
23. McPhail L.D., Chung Y.-L., Madhu B., et al. Tumor dose response to the vascular disrupting agent,5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11 (2005) 3705-3713
24. Arias-Mendoza F., Smith M.R., and Brown T.R. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol 11 (2004) 368-376
25. Bourne R.M., Stanwell P., Stretch J.R., et al. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur J Radiol 53 (2005) 506-513
26. Chang L., Miller B.L., McBride D., et al. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 197 (1995) 525-531
27. Panigrahy A., Krieger M.D., Gonzalez-Gomez I., et al. Untreated pediatric primitive neuroectodermal tumor in vivo: quantitation of taurine with MR Spectroscopy. Radiology 236 (2005) 1020-1025
28. Star-Lack J., Spielman D., Adalsteinsson E., et al. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson B 133 (1998) 243-254
29. 3) spatial resolution. Radiology 198 (1996) 795-805
30. Stanwell P., Gluch L., Clark D., et al. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol 15 (2005) 1037-1043
31. Mackinnon W.B., Barry P.A., Malycha P.L., et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 204 (1997) 661-666
32. Dixon R.M., and Frahm J. Localized proton MR spectroscopy of the human kidney in vivo by means of short echo time STEAM sequences. Magn Reson Med 31 (1994) 482-487
33. Tyszka J.M., and Silverman J.M. Navigated single-voxel proton spectroscopy of the human liver. Magn Reson Med 39 (1998) 1-5
34. Mohammad R.M., Wall N.R., Dutcher J.A., et al. The addition of Bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6 (2000) 4950-4956
35. Al-Katib A.M., Smith M.R., Kamanda W.S., et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4 (1998) 1305-1314
36. He Q., Shungu D.C., van Zijl P.C., et al. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J Magn Reson B 106 (1995) 203-211
37. He Q., Bhujwalla Z.M., and Glickson J.D. Proton detection of choline and lactate in EMT6 tumors by spin-echo-enhanced selective multiple-quantum-coherence transfer. J Magn Reson B 112 (1996) 18-25
38. Ackerstaff E., Glunde K., and Bhujwalla Z.M. Choline phospholipid metabolism: a target in cancer cells?. J Cell Biochem 90 (2003) 525-533
39. Dyke J.P., Zakian K.L., Spees W.M., et al. Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging. Clin Cancer Res 9 (2003) 4529-4536
40. Jagannathan N.R., Kumar M., Seenu V., et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84 (2001) 1016-1022
41. Bhujwalla Z.M., Shungu D.C., and Glickson J.D. Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging. Magn Reson Med 36 (1996) 204-211
42. Madhu B., Waterton J.C., Griffiths J.R., et al. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 8 (2006) 560-567
43. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
44. Bhujwalla Z.M., and Glickson J.D. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys 36 (1996) 635-639
45. Poptani H., Bansal N., Graham R.A., et al. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed 16 (2003) 102-111
46. Aboagye E.O., Bhujwalla Z.M., Shungu D.C., et al. Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res 58 (1998) 1063-1067
47. Aboagye E.O., Bhujwalla Z.M., He Q., et al. Evaluation of lactate as a 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat Res 150 (1998) 38-42
48. Artemov D., Bhujwalla Z.M., Pilatus U., et al. Two-compartment model for determination of glycolytic rates of solid tumors by in vivo 13C NMR spectroscopy. NMR Biomed 11 (1998) 395-404
49. Poptani H., Bansal N., Jenkins W.T., et al. Cyclophosphamide treatment modifies tumor oxygenation and glycolytic rates of RIF-1 tumors: 13C magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning. Cancer Res 63 (2003) 8813-8820
50. Rivenzon-Segal D., Margalit R., and Degani H. Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. Am J Physiol Endocrinol Metab 283 (2002) E623-E630
51. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 5 (1992) 303-324
52. Kumar M., Jagannathan N.R., Seenu V., et al. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 24 (2006) 325-332